Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1989 May;86(10):3842–3846. doi: 10.1073/pnas.86.10.3842

Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages.

J Szebeni 1, S M Wahl 1, M Popovic 1, L M Wahl 1, S Gartner 1, R L Fine 1, U Skaleric 1, R M Friedmann 1, J N Weinstein 1
PMCID: PMC287237  PMID: 2542948

Abstract

Dipyridamole (DPM) is commonly used as a coronary vasodilator and inhibitor of platelet aggregation in the treatment of cardiovascular diseases. We report here that DPM potentiates the inhibitory effects of 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine against human immunodeficiency virus type 1 (HIV-1) in human monocyte-macrophages. At the same concentrations, DPM does not potentiate the toxic effects of AZT on these cells or on human bone marrow (granulocyte-monocyte) progenitor cells. Since monocyte-macrophage lineage cells appear to be the major reservoir for HIV-1 in vivo, these findings suggest the possibility of using DPM or its analogues in combination chemotherapy of HIV infections.

Full text

PDF
3842

Images in this article

3843Image
on p.3843

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chou T. C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi: 10.1016/0065-2571(84)90007-4. [DOI] [PubMed] [Google Scholar]
  2. Dahlberg J. E., Mitsuya H., Blam S. B., Broder S., Aaronson S. A. Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A. 1987 Apr;84(8):2469–2473. doi: 10.1073/pnas.84.8.2469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. De Clercq E. Perspectives for the chemotherapy of AIDS. Anticancer Res. 1987 Sep-Oct;7(5B):1023–1038. [PubMed] [Google Scholar]
  4. DeStefano E., Friedman R. M., Friedman-Kien A. E., Goedert J. J., Henriksen D., Preble O. T., Sonnabend J. A., Vilcek J. Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy. J Infect Dis. 1982 Oct;146(4):451–459. doi: 10.1093/infdis/146.4.451. [DOI] [PubMed] [Google Scholar]
  5. Fine R. L., Koizumi S., Curt G. A., Chabner B. A. Effect of calcium channel blockers on human CFU-GM with cytotoxic drugs. J Clin Oncol. 1987 Mar;5(3):489–495. doi: 10.1200/JCO.1987.5.3.489. [DOI] [PubMed] [Google Scholar]
  6. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  7. FitzGerald G. A. Dipyridamole. N Engl J Med. 1987 May 14;316(20):1247–1257. doi: 10.1056/NEJM198705143162005. [DOI] [PubMed] [Google Scholar]
  8. Galabov A. S., Mastikova M. Dipyridamole is an interferon inducer. Acta Virol. 1982 May;26(3):137–147. [PubMed] [Google Scholar]
  9. Gartner S., Markovits P., Markovitz D. M., Kaplan M. H., Gallo R. C., Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science. 1986 Jul 11;233(4760):215–219. doi: 10.1126/science.3014648. [DOI] [PubMed] [Google Scholar]
  10. Grem J. L., Fischer P. H. Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels. Cancer Res. 1986 Dec;46(12 Pt 1):6191–6199. [PubMed] [Google Scholar]
  11. Hartshorn K. L., Vogt M. W., Chou T. C., Blumberg R. S., Byington R., Schooley R. T., Hirsch M. S. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother. 1987 Feb;31(2):168–172. doi: 10.1128/aac.31.2.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hasday J. D., Sitrin R. G. Dipyridamole stimulates urokinase production and suppresses procoagulant activity of rabbit alveolar macrophages: a possible mechanism of antithrombotic action. Blood. 1987 Feb;69(2):660–667. [PubMed] [Google Scholar]
  13. Kubota K., Mizoguchi H., Miura Y., Suda T., Takaku F. A new technique for the cytochemical examination of human hemopoietic cells grown in agar gel. Exp Hematol. 1980 Mar;8(3):339–344. [PubMed] [Google Scholar]
  14. Markman M., Chan T. C., Cleary S., Howell S. B. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole. Cancer Chemother Pharmacol. 1987;19(1):80–83. doi: 10.1007/BF00296262. [DOI] [PubMed] [Google Scholar]
  15. Marsh J. C. The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells: a review. Cancer Res. 1976 Jun;36(6):1853–1882. [PubMed] [Google Scholar]
  16. McDougal J. S., Martin L. S., Cort S. P., Mozen M., Heldebrant C. M., Evatt B. L. Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor. J Clin Invest. 1985 Aug;76(2):875–877. doi: 10.1172/JCI112045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehrman S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096–7100. doi: 10.1073/pnas.82.20.7096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Perno C. F., Yarchoan R., Cooney D. A., Hartman N. R., Gartner S., Popovic M., Hao Z., Gerrard T. L., Wilson Y. A., Johns D. G. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med. 1988 Sep 1;168(3):1111–1125. doi: 10.1084/jem.168.3.1111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pike B. L., Robinson W. A. Human bone marrow colony growth in agar-gel. J Cell Physiol. 1970 Aug;76(1):77–84. doi: 10.1002/jcp.1040760111. [DOI] [PubMed] [Google Scholar]
  20. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  21. Richman D. D. The treatment of HIV infection. AIDS. 1988;2 (Suppl 1):S137–S142. doi: 10.1097/00002030-198800001-00021. [DOI] [PubMed] [Google Scholar]
  22. Roy S., Wainberg M. A. Role of the mononuclear phagocyte system in the development of acquired immunodeficiency syndrome (AIDS). J Leukoc Biol. 1988 Jan;43(1):91–97. doi: 10.1002/jlb.43.1.91. [DOI] [PubMed] [Google Scholar]
  23. Shi M. M., Young J. D. [3H]dipyridamole binding to nucleoside transporters from guinea-pig and rat lung. Biochem J. 1986 Dec 15;240(3):879–883. doi: 10.1042/bj2400879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sipka S., Nagy K., Szegedi G. Adenosine induced delay of expression of AIDS virus, HIV, in H9T cells. Acta Biochim Biophys Hung. 1988;23(1):75–82. [PubMed] [Google Scholar]
  25. Sowemimo-Coker S. O., Kovacs I. B., Pickles H., Hedges A., Turner P. Dipyridamole increases red cell deformability. Br J Clin Pharmacol. 1983 Oct;16(4):423–425. doi: 10.1111/j.1365-2125.1983.tb02188.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Tonew E., Indulen M. K., Dzeguze D. R. Antiviral action of dipyridamole and its derivatives against influenza virus A. Acta Virol. 1982 May;26(3):125–129. [PubMed] [Google Scholar]
  27. Verschueren H., Wildemauwe C., Van Larebeke N. Effects of dipyridamole (Persantin R) on morphology and motility of mouse embryo cells. Cell Biol Int Rep. 1983 Apr;7(4):263–270. doi: 10.1016/0309-1651(83)90060-7. [DOI] [PubMed] [Google Scholar]
  28. Wahl L. M., Katona I. M., Wilder R. L., Winter C. C., Haraoui B., Scher I., Wahl S. M. Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). I. Characterization of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions by flow cytometric analysis. Cell Immunol. 1984 May;85(2):373–383. doi: 10.1016/0008-8749(84)90251-x. [DOI] [PubMed] [Google Scholar]
  29. Wahl S. M., Katona I. M., Stadler B. M., Wilder R. L., Helsel W. E., Wahl L. M. Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). II. Functional properties of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions. Cell Immunol. 1984 May;85(2):384–395. doi: 10.1016/0008-8749(84)90252-1. [DOI] [PubMed] [Google Scholar]
  30. Wahl S. M., McCartney-Francis N., Hunt D. A., Smith P. D., Wahl L. M., Katona I. M. Monocyte interleukin 2 receptor gene expression and interleukin 2 augmentation of microbicidal activity. J Immunol. 1987 Aug 15;139(4):1342–1347. [PubMed] [Google Scholar]
  31. Weber G. Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture. Cancer Res. 1983 Aug;43(8):3466–3492. [PubMed] [Google Scholar]
  32. Willson J. K., Fischer P. H., Tutsch K., Alberti D., Simon K., Hamilton R. D., Bruggink J., Koeller J. M., Tormey D. C., Earhart R. H. Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. Cancer Res. 1988 Oct 1;48(19):5585–5590. [PubMed] [Google Scholar]
  33. Woffendin C., Plagemann P. G. Interaction of [3H]dipyridamole with the nucleoside transporters of human erythrocytes and cultured animal cells. J Membr Biol. 1987;98(1):89–100. doi: 10.1007/BF01871048. [DOI] [PubMed] [Google Scholar]
  34. Yarchoan R., Klecker R. W., Weinhold K. J., Markham P. D., Lyerly H. K., Durack D. T., Gelmann E., Lehrman S. N., Blum R. M., Barry D. W. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986 Mar 15;1(8481):575–580. doi: 10.1016/s0140-6736(86)92808-4. [DOI] [PubMed] [Google Scholar]
  35. Yarchoan R., Perno C. F., Thomas R. V., Klecker R. W., Allain J. P., Wills R. J., McAtee N., Fischl M. A., Dubinsky R., McNeely M. C. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1988 Jan 16;1(8577):76–81. doi: 10.1016/s0140-6736(88)90283-8. [DOI] [PubMed] [Google Scholar]
  36. Yeh T. J., McBride P. T., Overall J. C., Jr, Green J. A. Automated, quantitative cytopathic effect reduction assay for interferon. J Clin Microbiol. 1982 Aug;16(2):413–415. doi: 10.1128/jcm.16.2.413-415.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Zimmerman T. P., Mahony W. B., Prus K. L. 3'-azido-3'-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem. 1987 Apr 25;262(12):5748–5754. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES